

CONTENTS

IMPORTANT NOTICE TO PROSPECTIVE [REDACTED]

This document is issued by our Company solely in connection with the [REDACTED] and the [REDACTED] and does not constitute an [REDACTED] to sell or a solicitation of an [REDACTED] to buy any security other than the [REDACTED] by this document pursuant to the [REDACTED]. This document may not be used for the purpose of making, and does not constitute, an [REDACTED] or invitation in any other jurisdiction or in any other circumstances. No action has been taken to permit a [REDACTED] of the [REDACTED] in any jurisdiction other than Hong Kong and no action has been taken to permit the distribution of this document in any jurisdiction other than Hong Kong. The distribution of this document for purposes of a [REDACTED] and the [REDACTED] and sale of the [REDACTED] in other jurisdictions are subject to restrictions and may not be made except as permitted under the applicable securities laws of such jurisdictions pursuant to registration with or authorization by the relevant securities regulatory authorities or an exemption therefrom.

You should rely only on the information contained in this document to make your [REDACTED] decision. The [REDACTED] is made solely on the basis of the information contained and the representations made in this document. We have not authorized anyone to provide you with information that is different from what is contained in this document. Any information or representation not contained nor made in this document must not be relied on by you as having been authorized by our Company, the Sole Sponsor, [REDACTED], any of our or their respective directors, officers, employees, agents, or representatives of any of them or any other parties involved in the [REDACTED]. Information contained on our website (www.ziyondpharma.com) does not form part of this document.

	<i>Page</i>
Expected Timetable	iv
Contents	vii
Summary	1
Definitions	12
Glossary of Technical Terms	21
Forward-looking Statements	26
Risk Factors	28
Waivers from Strict Compliance with the Listing Rules	55
Information about this Document and the [REDACTED]	58
Directors and Parties Involved in the [REDACTED]	62
Corporate Information	66
Industry Overview	68

CONTENTS

Regulatory Overview	80
History, Development and Corporate Structure	93
Business	109
Financial Information	173
Relationship with Our Controlling Shareholders	209
Share Capital	212
Substantial Shareholders	216
Directors and Senior Management	218
Future Plans and Use of [REDACTED]	228
[REDACTED]	230
Structure of the [REDACTED]	240
How to Apply for [REDACTED]	248
Appendix I	
Accountants’ Report	I-1
Appendix II	
Unaudited [REDACTED] Financial Information	II-1
Appendix III	
Property Valuation Report	III-1
Appendix IV	
Summary of Articles of Association	IV-1
Appendix V	
Statutory and General Information	V-1
Appendix VI	
Documents Delivered to the Registrar of Companies and Available on Display	VI-1